Year: 2026
Type: article
Study design: Observational Study
Abstract: ABSTRACT Purpose Advancing therapies have increased B‐cell Non‐Hodgkin's Lymphoma (B‐NHL) patient survival. However, data are limited on the risk of type II diabetes mellitus (type II DM) in adult survivors following treatment. This study examines the risk of type II DM among a Utah population of B‐NHL survivors, compared to the general population. Methods A cohort of 3529 adult survivors diagnosed with B‐NHL in Utah between 1997 and 2013 in the Utah Cancer Registry and 13,339 individuals from the general population were identified using the Utah Population Database (UPDB). Multivariate Cox Proportional Hazard models were used to estimate adjusted hazard ratios (aHR) for developing type II DM, stratified for time post‐diagnosis. Results Compared to the cancer‐free population, B‐NHL survivors had an overall increased risk of developing type II DM (HR: 1.49; 95% CI: 1.32, 1.69), largely within the first year (HR: 4.41; 95% CI: 3.52, 5.52) following diagnosis. Older B‐NHL survivors were more likely to develop type II DM at any time compared to survivors < 40 years [40–65 years (HR: 2.66; 95% CI 1.48–4.79); ≥ 65 years (HR: 3.77; 95% CI 2.09–6.78)]. Obese (BMI > 30 kg/m 2 ) survivors had a 4.06‐fold increase in the risk of type II DM compared to normal BMI (18–24.9 kg/m 2 ) cancer survivors. Cancer treatment did not increase the risk of type II DM compared to no treatment. Conclusions Adult B‐NHL cancer survivors were at an overall increased risk of developing type II DM compared to the general population, within the first year and overall, following a cancer diagnosis. This study provides evidence suggesting the importance of obesity prevention and improvement in care management oversight for B‐NHL survivorship and DM outcomes.
Source: Cancer Medicine
DOI: 10.1002/cam4.71367
Language: English
Topic: Cancer survivorship and care
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,700
Funders: Doris Duke Charitable Foundation, Intermountain Healthcare, Utah Department of Health, Utah State University, University of Utah, Huntsman Cancer Foundation, Huntsman Cancer Institute, Royal Hobart Hospital Research Foundation, Clifford Craig Foundation, Indian Institute of Technology Jodhpur, South African Medical Research Council, Fundação de Amparo à Pesquisa do Estado de São Paulo, National Natural Science Foundation of China, Svenska Forskningsrådet Formas, Asthma Australia, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, King Saud University, Ministero della Salute, Natural Science Foundation of Fujian Province, National Research Foundation of Korea, Natural Science Foundation of Hebei Province, Princess Nourah Bint Abdulrahman University, Vetenskapsrådet, Natural Science Foundation of Jiangxi Province, Ministerio de Ciencia e Innovación, Natural Science Foundation of Shandong Province, King Khalid University, Tarim University, Bayerisches Staatsministerium für Umwelt und Verbraucherschutz, Putian University, Anhui Provincial Department of Education, Key Research and Development Program of Jiangxi Province, Merz Pharmaceuticals, Hebei Provincial Key Research Projects, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Helen Macpherson Smith Trust, Suzhou University, National Institutes of Health, Center for Clinical and Translational Science, University of Utah, National Health and Medical Research Council, Japan Society for the Promotion of Science, Natural Science Foundation of Anhui Province, Agencia Estatal de Investigación, National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province, National Cancer Institute, National Institute of Allergy and Infectious Diseases, NIH Clinical Center, Wellcome Leap
OpenAlex ID: W7122356594